## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.8% below STRENGTH zone (3.0-6.0%); PEG 1.96 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($215.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Danaher Corporation (DHR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation**
- Source: KGET.com | 20251218T160813 | Somewhat-Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by Danaher Corporation (NYSE: DHR). The firm encourages investors who purchased Danaher securities before April 21, 2022, and still hold them, to contact them to assist with the investigation. This investigation specifically concerns whether Danaher and its officers/directors engaged in corporate wrongdoing.

**2. Will Strength in Biotechnology Unit Continue to Drive Danaher's Growth?**
- Source: TradingView â€” Track All Markets | 20251218T150802 | Bullish | Relevance: 100%
- Danaher Corporation's Biotechnology segment has shown strong growth, particularly in bioprocessing, driven by demand for consumables and monoclonal antibodies. Despite concerns about declining protein research equipment demand, the segment is expected to continue its steady performance due to recurring product demand. The article also compares Danaher's performance with peers like CVS Health and Labcorp and provides its valuation and estimates.

**3. Dudley & Shanley Inc. Has $22.79 Million Stake in Danaher Corporation $DHR**
- Source: MarketBeat | 20251218T095506 | Bullish | Relevance: 100%
- Dudley & Shanley Inc. increased its stake in Danaher Corporation (NYSE:DHR) by 4.9% to 114,941 shares, valued at $22.79 million, making it their 13th largest holding. Danaher exceeded quarterly earnings and revenue estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $248.25. Institutional ownership is high, although company insiders sold approximately 30,248 shares last quarter.

**4. Danaher Schedules Fourth Quarter 2025 Earnings Conference Call**
- Source: Yahoo Finance | 20251217T220748 | Neutral | Relevance: 100%
- Danaher Corporation announced it will webcast its Q4 2025 earnings call on January 28, 2026, at 8:00 a.m. ET. The company will discuss financial performance and future expectations, with access available via webcast and dial-in. A replay will also be provided.

**5. Jefferies Adjusts Price Target on Danaher to $255 From $245, Maintains Buy Rating**
- Source: marketscreener.com | 20251217T120755 | Somewhat-Bullish | Relevance: 100%
- Jefferies has increased its price target for Danaher Corporation (DHR) to $255 from $245 while maintaining a Buy rating on the stock. This adjustment reflects the analyst firm's updated outlook for the advanced medical equipment and technology company. The article also lists recent news and analyst actions regarding Danaher.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $240 | $230 | +4% |
| 2025-12-09 | Goldman Sachs | $265 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.0% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $76M sold (10 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.96 elevated, pricing in significant growth expectations. Forward P/E 26.7x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $161.0B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.96 |
| Forward P/E | 26.7 |
| Current P/E | 29.1 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.2% to -0.8% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.93), momentum weakening. RSI neutral at 51. OFD pattern: -DBH (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.75% (CS: 40) | Neutral |
| RSI_14 | 51.4 | Neutral |
| MACD Histogram | -0.93 | Bearish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 1.023x | Above |
| vs SMA200 | 1.103x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $224.84
- **Stop Loss:** $215.42 (4.2% risk)
- **Target:** $234.26 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 127
- **Position Value:** $28,554.68
- **Portfolio %:** 28.55%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*